Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis
Copyright © 2018 by the American Society of Nephrology..
BACKGROUND AND OBJECTIVES: Hydroxychloroquine is widely used in patients with rheumatoid arthritis. However, large-scale studies examining the long-term effects of hydroxychloroquine on the development of kidney disease in patients with rheumatoid arthritis are lacking. We aimed to assess the long-term association of hydroxychloroquine use with the risk of developing CKD in this population.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an observational cohort study for patients with newly diagnosed rheumatoid arthritis who were enrolled prospectively in Taiwan's National Health Insurance Research Database between January 1, 2000 and December 31, 2013. We used multivariable Cox proportional hazard regression to analyze the association of hydroxychloroquine use with incident CKD.
RESULTS: A total of 2619 patients, including 1212 hydroxychloroquine users and 1407 hydroxychloroquine nonusers, were analyzed. Incident CKD was reported in 48 of 1212 hydroxychloroquine users and 121 of 1407 hydroxychloroquine nonusers. The incidence rate of CKD was lower in hydroxychloroquine users than in hydroxychloroquine nonusers (10.3 versus 13.8 per 1000 person-years). After multivariable adjustment, hydroxychloroquine users still had a lower risk of incident CKD (adjusted hazard ratio, 0.64; 95% confidence interval, 0.45 to 0.90; P=0.01) than hydroxychloroquine nonusers. The lower risk of subsequent CKD development was dose dependent and consistent across subgroup analyses.
CONCLUSIONS: Hydroxychloroquine use in patients with newly diagnosed rheumatoid arthritis is associated with a significantly lower risk of incident CKD compared with in nonusers.
| Errataetall: |
CommentIn: Clin J Am Soc Nephrol. 2018 May 7;13(5):679-680. - PMID 29661771 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Clinical journal of the American Society of Nephrology : CJASN - 13(2018), 5 vom: 07. Mai, Seite 702-709 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Chia-Lin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.11.2019 Date Revised 15.08.2023 published: Print-Electronic CommentIn: Clin J Am Soc Nephrol. 2018 May 7;13(5):679-680. - PMID 29661771 Citation Status MEDLINE |
|---|
| doi: |
10.2215/CJN.11781017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283101148 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283101148 | ||
| 003 | DE-627 | ||
| 005 | 20231225035637.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2215/CJN.11781017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0943.xml |
| 035 | |a (DE-627)NLM283101148 | ||
| 035 | |a (NLM)29661770 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Chia-Lin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2019 | ||
| 500 | |a Date Revised 15.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin J Am Soc Nephrol. 2018 May 7;13(5):679-680. - PMID 29661771 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 by the American Society of Nephrology. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: Hydroxychloroquine is widely used in patients with rheumatoid arthritis. However, large-scale studies examining the long-term effects of hydroxychloroquine on the development of kidney disease in patients with rheumatoid arthritis are lacking. We aimed to assess the long-term association of hydroxychloroquine use with the risk of developing CKD in this population | ||
| 520 | |a DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an observational cohort study for patients with newly diagnosed rheumatoid arthritis who were enrolled prospectively in Taiwan's National Health Insurance Research Database between January 1, 2000 and December 31, 2013. We used multivariable Cox proportional hazard regression to analyze the association of hydroxychloroquine use with incident CKD | ||
| 520 | |a RESULTS: A total of 2619 patients, including 1212 hydroxychloroquine users and 1407 hydroxychloroquine nonusers, were analyzed. Incident CKD was reported in 48 of 1212 hydroxychloroquine users and 121 of 1407 hydroxychloroquine nonusers. The incidence rate of CKD was lower in hydroxychloroquine users than in hydroxychloroquine nonusers (10.3 versus 13.8 per 1000 person-years). After multivariable adjustment, hydroxychloroquine users still had a lower risk of incident CKD (adjusted hazard ratio, 0.64; 95% confidence interval, 0.45 to 0.90; P=0.01) than hydroxychloroquine nonusers. The lower risk of subsequent CKD development was dose dependent and consistent across subgroup analyses | ||
| 520 | |a CONCLUSIONS: Hydroxychloroquine use in patients with newly diagnosed rheumatoid arthritis is associated with a significantly lower risk of incident CKD compared with in nonusers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Arthritis, Rheumatoid | |
| 650 | 4 | |a Cohort Studies | |
| 650 | 4 | |a Confidence Intervals | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Incidence | |
| 650 | 4 | |a National Health Programs | |
| 650 | 4 | |a Proportional Hazards Models | |
| 650 | 4 | |a Renal Insufficiency, Chronic | |
| 650 | 4 | |a Risk | |
| 650 | 4 | |a Taiwan | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Chang, Chia-Chu |e verfasserin |4 aut | |
| 700 | 1 | |a Kor, Chew-Teng |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Tao-Hsiang |e verfasserin |4 aut | |
| 700 | 1 | |a Chiu, Ping-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Tarng, Der-Cherng |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Chih-Cheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical journal of the American Society of Nephrology : CJASN |d 2006 |g 13(2018), 5 vom: 07. Mai, Seite 702-709 |w (DE-627)NLM172123720 |x 1555-905X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2018 |g number:5 |g day:07 |g month:05 |g pages:702-709 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2215/CJN.11781017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2018 |e 5 |b 07 |c 05 |h 702-709 | ||